证券代码：002388 证券简称：新亚制程 公告编号：2026-007 新亚制程（浙江）股份有限公司 登录新浪财经APP 搜索【信披】查看更多考评等级 关于董事会延期换届的提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记载、误导性陈述或者重大遗 漏。 新亚制程（浙江）股份有限公司（以下简称"公司"）第六届董事会将于2026年2月15日任期届满，鉴于 公司新一届董事会董事候选人的提名工作尚未完成，为保障公司董事会工作的连续性和稳定性，公司第 六届董事会将延期换届。公司第六届董事会成员、董事会各专门委员会委员和高级管理人员任期亦相应 顺延。 在换届选举工作完成之前，公司第六届董事会成员、董事会各专门委员会委员和高级管理人员将根据法 律法规和《公司章程》的有关规定，继续履行董事及高级管理人员的义务和职责。 公司董事会延期换届不会影响公司的正常运营。公司将积极推进董事会的换届工作，并及时履行相关的 信息披露义务。 特此公告。 新亚制程（浙江）股份有限公司 董事会 2026年2月12日 证券代码：002388 证券简称：新亚制程 公告编号：2026-008 截至本公告披露日，陈多佳女士直接持 ...

股票可能被终止上市的第二次风险提示公告 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002305 证券简称：*ST南置 公告编号：2026-004号 南国置业股份有限公司 1.南国置业股份有限公司（以下简称"公司"）于2025年4月29日在指定信息披露媒体上披露了《关于公 司股票交易被实施退市风险警示及其他风险警示暨停牌的公告》，公司股票于2025年4月30日开市起被 实施退市风险警示。若公司2025年度出现《深圳证券交易所股票上市规则》（以下简称"《股票上市规 则》"）第9.3.12条规定的情形，公司股票存在被终止上市的风险。 2.根据《股票上市规则》第9.3.6条的规定："上市公司因触及本规则第9.3.1条第一款第一项至第三项情 形，其股票交易被实施退市风险警示后，应当在其股票交易被实施退市风险警示当年会计年度结束后一 个月内，披露股票可能被终止上市的风险提示公告，在首次风险提示公告披露后至年度报告披露前，每 十个交易日披露一次风险提示公告。"公司属于应披露股票可能被终止上市的风险提示公告的情形。敬 请广大投资者理性投资，注意风险。 已被实施财务类退市风险警示的情形： ■ 一、公司股票可能 ...

Core Viewpoint - Zhejiang Kangnbei Pharmaceutical Co., Ltd. announced that its subsidiaries have been selected for the continuation procurement of certain drugs under the national organized procurement program, which is expected to positively impact the company's sales and market share [1][2]. Group 1: Selected Drugs Information - The company’s subsidiaries participated in the national organized procurement for the continuation of drugs, with 11 products including Tamsulosin Hydrochloride Sustained-Release Capsules and Piperacillin Sodium and Tazobactam Sodium for Injection being selected [1]. - The procurement period for the selected drugs will last until December 31, 2028, starting from the implementation of the selection results [1]. Group 2: Financial Impact - The total sales revenue from the selected drugs for 2024 is projected to be 385.29 million, accounting for 5.91% of the company's total revenue of 6.52 billion for the same year [2]. - For the first three quarters of 2025, the projected sales revenue from these drugs is 296.15 million, representing 5.95% of the company's revenue of 4.98 billion [2]. - The selected drugs are expected to maintain stable or declining prices, which will help the company expand sales and enhance brand influence [2].

Core Viewpoint - Tianyao Pharmaceutical Co., Ltd. and its subsidiaries have participated in the national centralized procurement for drugs whose agreements have expired, with some products expected to be selected for the continuation of procurement [1][2]. Group 1: Selected Products Information - The company and its subsidiaries are involved in the national centralized procurement for drugs, with results expected to be finalized by the end of March 2026 [1]. - The specific details of the selected drugs will be based on the final data released by the procurement office [1]. Group 2: Impact on the Company - The selected drugs are projected to generate sales revenue of approximately RMB 323 million in 2024, accounting for 10.03% of the company's total revenue for that period [2]. - For the first three quarters of 2025, the expected sales revenue from these drugs is RMB 250 million (unaudited), representing 11.20% of the company's revenue for that timeframe [2]. - The implementation of the procurement results is anticipated to enhance product sales, increase market share, improve brand image, and promote the development of the company's formulation business [2].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688667 证券简称：菱电电控 公告编号：2026-009 武汉菱电汽车电控系统股份有限公司 关于终止发行股份及支付现金购买资产事项相关主体 买卖股票情况自查报告的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 武汉菱电汽车电控系统股份有限公司（以下简称"上市公司"、"公司"或"菱电电控"）于2026年1月30日 召开第四届董事会第八次会议，审议通过了《关于终止发行股份及支付现金购买资产事项并撤回申请文 件的议案》，同意公司终止发行股份及支付现金购买资产事项（以下简称"本次交易"）并撤回申请文 件，同时授权公司管理层全权办理本次交易终止的各项事宜。具体内容详见公司于2026年1月31日在上 海证券交易所网站（www.sse.com.cn）披露的《武汉菱电汽车电控系统股份有限公司关于终止发行股份 及支付现金购买资产事项并撤回申请文件的公告》（公告编号：2026-005）。 根据《上市公司重大资产重组管理办法》《公开发行证券的公司信息披露内容与格式准则第26号一一 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 江苏九鼎新材料股份有限公司 第十一届董事会第九次临时会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、董事会会议召开情况 江苏九鼎新材料股份有限公司（以下简称"公司"）第十一届董事会第九次临时会议于2026年2月9日以书 面形式及电子邮件等方式通知全体董事、高级管理人员，会议于2026年2月12日以现场及通讯方式召 开。会议应出席董事9人，实际出席董事9人，其中董事王皓先生、董事王翔先生、独立董事姜林先生、 独立董事于守富先生以通讯方式参加。会议由董事长顾清波先生主持，公司高级管理人员列席了会议， 符合法律、行政法规、部门规章和《公司章程》的规定，合法有效。 证券代码：002201 证券简称：九鼎新材 公告编号：2026-8 二、董事会会议审议情况 经与会董事认真审议，采用记名投票和通讯表决的方式通过以下议案： 1、以9票同意、0票反对、0票弃权审议通过了《关于公司投资建设"特种玻璃纤维涡卷毡技术改造项 目"的议案》，本议案尚需提交股东会审议。 《关于公司投资建设"特种玻璃纤维涡卷毡技术改造项目 ...

Group 1 - The company held its 13th meeting of the 4th Board of Directors on February 12, 2026, to discuss and approve a proposal regarding the provision of equity pledge guarantees and related transactions [2][3] - The proposal was approved with 7 votes in favor, 0 against, and 0 abstentions, with 2 members abstaining due to conflicts of interest [2][3] - The company’s wholly-owned subsidiary, Shenzhen Yihong Investment Co., Ltd., plans to provide a pledge guarantee for a fixed asset loan of 375 million yuan to its associate company, Shenzhen Yifeng Zhixin Packaging Technology Co., Ltd. [2][31] Group 2 - The proposal will be submitted to the shareholders' meeting for further approval [4][9] - The company has received a request from a major shareholder to add the proposal to the agenda of the upcoming shareholders' meeting [9][10] - The shareholders' meeting is scheduled for February 25, 2026, and will combine on-site voting with online voting [11][12] Group 3 - The company’s total external guarantee amount is 203.5 million yuan, with the new guarantee increasing the total to 138.91 million yuan, which represents 67.40% of the company's latest audited net assets [46] - The company has no overdue guarantees or guarantees involved in litigation [46]

Meeting Details - The first extraordinary general meeting of shareholders for 2026 was held on February 12, 2026, at 14:00 [2] - The meeting took place at the company's conference room located at 42 Kunlun Mountain Road, Tieling County, Tieling City [3] - The meeting was conducted through a combination of on-site and online voting [4] - The meeting was convened by the company's board of directors, with Chairman Wang Haibo presiding [5][6] Attendance - A total of 187 shareholders attended the meeting, representing 292,187,450 shares, which accounts for 35.4256% of the total voting shares [7] - Among them, 2 shareholders attended in person, representing 282,857,500 shares (34.2944%), while 185 shareholders participated via online voting, representing 9,329,950 shares (1.1312%) [8] Voting Results - The proposal regarding the estimated guarantee limit for the company and its subsidiaries for 2026 was approved, with 290,104,218 shares in favor (99.2870%) and 1,715,732 shares against (0.5872%) [13] - For small and medium shareholders, 7,246,718 shares voted in favor (77.6716%), while 1,715,732 shares opposed (18.3895%) [14] - The proposal to amend the "Special Incentive Management System" was also approved, with 290,429,818 shares in favor (99.3985%) and 1,389,132 shares against (0.4754%) [15] - Small and medium shareholders voted 7,572,318 shares in favor (81.1614%) for the amendment [16] Legal Opinion - The legal representatives from Beijing Zhonglun Law Firm confirmed that the meeting's convening, attendance, and voting procedures complied with relevant laws and regulations, deeming the voting results valid [18]

Meeting Overview - The first temporary shareholders' meeting of 2026 was convened by the company's board of directors [3] - The meeting was held on February 12, 2026, at 2:30 PM, combining on-site and online voting [3][4] - The meeting location was at the 11th floor of the Yunda Central Plaza, Changsha, Hunan Province [4] Attendance Details - As of the registration date on February 9, 2026, the total share capital of the company was 1,042,253,858 shares, with 1,012,420,986 shares eligible for voting [5] - The meeting was attended by some directors, senior management, and a witnessing lawyer [6] Voting and Legal Opinions - Shareholders and their authorized representatives voted on the submitted proposals using a combination of on-site and online methods [7] - The legal opinion from Hunan Qiyuan Law Firm confirmed that the meeting's procedures complied with relevant laws and regulations [7]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688177 证券简称：百奥泰 公告编号：2026-010 百奥泰生物制药股份有限公司 关于GotenfiaR（戈利木单抗注射液）获欧洲EMA上市批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 百奥泰生物制药股份有限公司（以下简称"百奥泰"或"公司"）于近日收到欧洲药品管理局（以下简 称"EMA"）签发的关于GotenfiaR（BAT2506，戈利木单抗注射液）上市批准通知。 GotenfiaR作为百奥泰又一个获得EMA上市批准的产品，将进一步拓展公司国际化市场，提升公司产品 的国际影响力，有望对公司长期经营业绩产生积极影响。已上市竞品和其他潜在竞品可能会拥有先行者 优势，GotenfiaR可能在未来面临激烈的市场竞争。 考虑到医药产品具有高科技、高风险、高附加值的特点，药品的前期研发以及产品从研制、临床试验报 批到投产的周期长，易受到技术、审批、政策等多方面因素的影响，未来产品市场竞争形势均存在诸多 不确定性，敬请广大投资者谨慎决策，注意投资风险，公 ...